Matarin Capital Management’s Biogen BIIB Stock Holding History

Matarin Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,860	Closed	-$3.08M	–	189
2020 Q3	$3.08M	Sell	10,860 -116	-1%	-$32.4K	0.65%	70
2020 Q2	$2.94M	Sell	10,976 -21	-0.2%	-$6.31K	0.59%	77
2020 Q1	$3.48M	Sell	10,997 -2,806	-20%	-$852K	0.54%	90
2019 Q4	$4.1M	Sell	13,803 -3,365	-20%	-$934K	0.39%	119
2019 Q3	$4M	Buy	+17,168	New	+$4M	0.3%	120
2017 Q2	–	Sell	-12,543	Closed	-$3.43M	–	277
2017 Q1	$3.43M	Sell	12,543 -549	-4%	-$155K	0.34%	117
2016 Q4	$3.71M	Buy	13,092 +11,283	+624%	+$3.34M	0.42%	92
2016 Q3	$566K	Buy	+1,809	New	+$536K	0.06%	195
2014 Q4	–	Sell	-3,566	Closed	-$1.18M	–	150
2014 Q3	$1.18M	Sell	3,566 -167	-4%	-$55.1K	0.54%	87
2014 Q2	$1.18M	Buy	3,733 +1,410	+61%	+$424K	0.52%	88
2014 Q1	$711K	Buy	+2,323	New	+$737K	0.42%	92
2013 Q4	–	Sell	-953	Closed	-$229K	–	127
2013 Q3	$229K	Sell	953 -24	-2%	-$5.37K	0.19%	153
2013 Q2	$210K	Buy	+977	New	+$209K	0.21%	151

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Matarin Capital Management's BIIB Position: Q4 2020 in Review

Matarin Capital Management sold out of Biogen (BIIB) in Q4 2020, closing a stake of 10,860 shares — an estimated $3.08M sold.

Matarin Capital Management first reported a position in BIIB in Q2 2013 and held it in 13 quarters. The position peaked at $4.1M in Q4 2019. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

Matarin Capital Management reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
Matarin Capital Management sold 10,860 Biogen shares in Q4 2020, an estimated $3.08M.
Matarin Capital Management first reported a position in Biogen in Q2 2013 and held it in 13 quarters.
Matarin Capital Management's Biogen position peaked at $4.1M in Q4 2019.
1,062 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.